Human-cell-based in-vitro bioassay for alzheimer's research
A novel in-vitro bioassay using human cell lines to study Alzheimer's disease mechanisms. This platform replicates key AD pathologies, aiding drug discovery and reducing animal testing.
Overview
This innovative in-vitro bioassay leverages human cell lines to study the mechanisms of Alzheimer's disease (AD). By activating the MAPK and NF-κB signaling pathways with small molecules PAF-C16 and BetA, the model induces Aβ aggregation and Tau phosphorylation, replicating key AD pathologies. This human-relevant model provides critical insights into neurodegeneration, facilitating drug discovery and target validation while reducing reliance on animal testing.
Technical specifications
- Human Cell Lines Used: Neurons (SH-SY5Y), Microglia (HMC3), Astrocytes (U-118 MG), and components of the blood-brain barrier like HBVP.
- 3D Culture System: Integrates various brain cells to mimic human brain environments more realistically.
- Molecule Activation: Uses PAF-C16 and BetA to activate MEK1/2-ERK and NF-κB pathways.
- Nanoparticle Encapsulation: Enhances targeted delivery and real-time tracking of molecules.
- In Vivo Testing: Administers NP-encapsulated molecules to wild-type mice intranasally to observe cognitive and behavioral responses.
Technology readiness level
This bioassay is currently at Technology Readiness Level 3 (TRL 3), where it has been validated in a laboratory setting with plans for further testing in vivo to enhance its applicability and accuracy for studying Alzheimer's disease.
About Tufts University
Tufts University is a comprehensive private research university with campuses in Medford/Somerville, Boston, and Grafton. Its Boston health sciences campus connects faculty with clinicians through hospital affiliations, while the Tufts Clinical and Translational Science Institute provides resources that support the full spectrum of clinical research and multi-site trials. The co-location of the Jean Mayer USDA Human Nutrition Research Center on Aging offers a federal–university platform for large-scale, population-relevant studies and collaboration. Research is supported by competitive federal funding, including NIH and USDA, among other sources. A centralized technology commercialization office manages IP, licensing, startup support, and industry-sponsored research agreements.
delivered to your inbox.